TY - JOUR
T1 - HSP60 and HSP10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease
AU - Anzalone, Rita
AU - Cappello, Francesco
AU - La Rocca, Giampiero
AU - Rappa, Francesca
AU - Zummo, Giovanni
AU - David, Sabrina
AU - Di Stefano, Antonino
AU - D'Anna, Silvestro E.
AU - Balbi, Bruno
AU - Donner, Claudio F.
AU - Magno, Francesca
AU - D'Anna, Silvestro E.
AU - Magno, Francesca
AU - D'Anna, Salvatore
PY - 2006
Y1 - 2006
N2 - BACKGROUND. The relation between smoking, chronic obstructive pulmonary disease (COPD), and lung cancer (LC) is an open field of investigation. A higher frequencyof adenocarcinoma has been reported in patients with COPD. Heat shockproteins (Hsps) are implicated in tumoral cell growth and differentiation. The aimof the present study was to investigate the expression of Hsp60 and Hsp10 in bronchialbiopsies from smokers with COPD and in 10 lung cancer patients and to evaluate the association between Hsps expression and carcinogenetic steps of LC. METHODS. An immunohistochemical study was performed for Hsp60 and Hsp10 in bronchial biopsies from 35 COPD (postbronchodilator forced expiratory volume in 1 second [FEV1]: 53±19% [mean ± SD]) patients with a history of smoking (53±34 pack/years) and in 10 patients with adenocarcinoma or adenosquamous carcinoma (ASC). Immunopositivity was quantified in the bronchial epithelium and in specimens with ASC. RESULTS. In smokers with COPD, 10 out of 35 patients had a normal bronchial epithelium (NBE), 12 showed basal cell hyperplasia (BCH), 5 squamous metaplasia(SM), and 8 dysplasia (Dy). It was found that 58 ± 23% and 54 ± 23% of NBE and48 ± 29% and 52 ± 26% of BCH expressed Hsp60 and Hsp10, respectively; in contrast, only 3 ± 3% and 3.6 ± 2% of SM, 1.9 ± 4% and 1.1 ± 2% of Dy expressed Hsp60 and Hsp10, respectively. ASC specimens were negative for Hsps proteins. Interestingly, NBE also present at the edges of ASC specimens was negative for Hsps proteins.CONCLUSIONS. The loss of Hsp60 and Hsp10 immunopositivity is related to the development and progression of bronchial cancer in smokers with COPD.
AB - BACKGROUND. The relation between smoking, chronic obstructive pulmonary disease (COPD), and lung cancer (LC) is an open field of investigation. A higher frequencyof adenocarcinoma has been reported in patients with COPD. Heat shockproteins (Hsps) are implicated in tumoral cell growth and differentiation. The aimof the present study was to investigate the expression of Hsp60 and Hsp10 in bronchialbiopsies from smokers with COPD and in 10 lung cancer patients and to evaluate the association between Hsps expression and carcinogenetic steps of LC. METHODS. An immunohistochemical study was performed for Hsp60 and Hsp10 in bronchial biopsies from 35 COPD (postbronchodilator forced expiratory volume in 1 second [FEV1]: 53±19% [mean ± SD]) patients with a history of smoking (53±34 pack/years) and in 10 patients with adenocarcinoma or adenosquamous carcinoma (ASC). Immunopositivity was quantified in the bronchial epithelium and in specimens with ASC. RESULTS. In smokers with COPD, 10 out of 35 patients had a normal bronchial epithelium (NBE), 12 showed basal cell hyperplasia (BCH), 5 squamous metaplasia(SM), and 8 dysplasia (Dy). It was found that 58 ± 23% and 54 ± 23% of NBE and48 ± 29% and 52 ± 26% of BCH expressed Hsp60 and Hsp10, respectively; in contrast, only 3 ± 3% and 3.6 ± 2% of SM, 1.9 ± 4% and 1.1 ± 2% of Dy expressed Hsp60 and Hsp10, respectively. ASC specimens were negative for Hsps proteins. Interestingly, NBE also present at the edges of ASC specimens was negative for Hsps proteins.CONCLUSIONS. The loss of Hsp60 and Hsp10 immunopositivity is related to the development and progression of bronchial cancer in smokers with COPD.
KW - chaperone expression
KW - lung obstruction
KW - lung tumors
KW - smoking
KW - chaperone expression
KW - lung obstruction
KW - lung tumors
KW - smoking
UR - http://hdl.handle.net/10447/39770
UR - http://www3.interscience.wiley.com/cgi-bin/fulltext/113399511/PDFSTART
M3 - Article
SN - 0008-543X
VL - 107
SP - 2417
EP - 2424
JO - Cancer
JF - Cancer
ER -